DXR

Daxor Corporation is a healthcare company within the medical instruments and supplies industry. With a market capitalization of $72.35 million, it operates at a relatively small scale compared to its sector peers. Revenue for the trailing twelve months (TTM) stands at $66,306. From a financial health perspective, Daxor's profitability metrics are notably high, with a gross margin of 100.0% and a profit margin of 2710.8%. However, these numbers are likely influenced by low revenue and expenses, as evidenced by an operating margin of -1509.5%. The company's returns on equity (ROE) and assets (ROA) are also divergent, at 5.3% and -2.5%, respectively. From a balance sheet perspective, Daxor has debt of $262,927 but its debt-to-equity ratio is moderate at 0.74. In terms of valuation context, the price to book ratio for Daxor is 2.01, while the price to sales ratio stands at 1091.23. The company's P/E ratio (TTM) is 95.73. Revenue growth has been negative over the year, with a decline of -74.4%.